In the following video, Motley Fool health-care analyst David Williamson highlights one pharmaceutical company that has no interest in organic growth. Valeant Pharmaceuticals (BHC -0.08%) is continuing its growth-through-acquisition strategy with the purchase of Obagi Medical Products (NASDAQ: OMPI), its 21st acquisition since 2011, for $344 million. David tells investors why this is a win for both parties, and how they should think of the investing thesis behind Valeant.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Valeant Continues to Devour
NYSE: BHC
Bausch Health Companies

The pharma continues to gobble up smaller business snacks.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.